Treating Multiple Myeloma in Europe Region
Emerging and Practical Concepts in Multiple Myeloma
Overview
In recent years, progress in the understanding of multiple myeloma has led to novel therapies that are rapidly changing treatment paradigms. Aptitude Health developed the Global Multiple Myeloma Academy to help physicians who treat multiple myeloma bridge the gap between innovation and implementation in patient care.
Date and Location
April 29–30, 2026; Virtual Meeting
Chair
Rafael Fonseca, MD
Mayo Clinic Cancer Center, USA
Co-Chair
Philippe Moreau, MD
University Hospital of Nantes, France
Faculty
Hermann Einsele, MD
Universitätsklinikum Würzburg; Germany
María-Victoria Mateos, MD, PhD
University of Salamanca, Spain
|
Agenda |
This virtual program will be held over 2 days. |
Day 1: Wednesday, April 29, 2026
17.00 – 20.00 Central European Summer Time
| Time (CEST) | Topic | Presenter |
| 17.00 – 17.10 | Welcome and Meeting Overview • Introduction to audience response system (ARS) |
Rafael Fonseca, MD |
| 17.10 – 17.45 | Overview of Later-Line Relapsed/Refractory Multiple Myeloma (RRMM) Treatment and Management | |
| 17.45 – 18.20 | Bispecific Antibodies in RRMM | |
| 18.20 – 18.35 | Break | |
| 18.35 – 19.05 | Immunotherapy Sequencing in RRMM: Current and Future Landscape | |
| 19.05 – 19.40 | Panel Discussion: Patient Case Debate – RRMM | |
| 19.40 – 20.00 | Final ARS Questions and Concluding Remarks | Rafael Fonseca, MD |
Day 2: Thursday, April 30, 2026
17.00 – 20.00 Central European Summer Time
| Time (CEST) | Topic | Presenter |
| 17.00 – 17.10 |
Welcome and Meeting Overview
|
Rafael Fonseca, MD |
| 17.10 – 17.30 | Overview of Relapsed/Refractory Multiple Myeloma (RRMM) Treatment: Early Lines of Therapy | |
| 17.30 – 17.50 | CAR T-Cell Therapy in RRMM: Impact of Earlier Use and Real-World Data | |
| 17.50 – 18.10 | Treatment Options for Non–CAR T-Cell Candidates | |
| 18.10 – 18.25 | Break | |
| 18.25 – 19.20 | Patient Case Discussion: RRMM | Regional case presenter All faculty |
| 19.20 – 19.50 | Future Directions in Early Lines of Therapy for RRMM | |
| 19.50 – 20.00 | ARS Questions and Session Close | Rafael Fonseca, MD |
